12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ReoPro abciximab: Phase IV data

Researchers at Deutsches Herzzentrum and colleagues reported data from the double-blind, international Phase IV ISAR-REACT 4 trial in 1,721 patients with acute with non-ST-segment-elevation myocardial infarction (NSTEMI) undergoing PCI showing that ReoPro plus unfractionated heparin missed the primary endpoint of significantly reducing a composite of death, MI, urgent TVR and major bleeding at 30 days vs. bivalirudin (10.9% vs. 11%, p=0.94). ReoPro...

Read the full 297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >